Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Foghorn Therapeutics (FHTX – Research Report) yesterday and set a price ...

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic ...

In summary, these BLI data demonstrate that B. subtilis MinD is capable of binding membrane in both monomeric and dimeric form, while the presence of ATP in the binding pocket appears to affect both ...

Elevated sodium levels in tumors boost T-cell metabolic fitness and cytotoxicity, revealing potential avenues for improving ...

A new process, nucleophagy, repairs damaged DNA that is particularly relevant for patients undergoing colorectal cancer ...

USF faculty continually demonstrate their skills in conducting high-impact research and innovation to advance frontiers of ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN ...

An ATPase import motor is believed to provide the pulling force from the stromal side to drive the translocation of preproteins, which is essential for the development and biogenesis of chloroplasts.

Kelly Shi, an analyst from Jefferies, has initiated a new Buy rating on Foghorn Therapeutics (FHTX). Kelly Shi’s rating is based on the ...

a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and ...